Mark Emalfarb
Patrimonio netto: 4 M $ in data 30/06/2026
Patrimonio netto: 4 M $ in data 30/06/2026
Mark A. Emalfarb is the founder of Dyadic International, Inc., founded in 1979, holding the title of Chief Executive Officer & Director.
Current jobs include Chairman & Chief Executive Officer at Dyadic International (USA), Inc., and Director at Biotechnology Development for Industry in Pharmaceuticals SLU since 2017.
Education includes an undergraduate degree from the University of Iowa, conferred in 1977.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 24/04/2026 | 4.832.667 ( 13,26% ) | 4 M $ | 30/06/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| DYADIC INTERNATIONAL, INC. | Fondatore | 01/01/1979 |
Dyadic International (USA), Inc.
Dyadic International (USA), Inc. BiotechnologyHealth Technology Researches and manufactures genes | Amministratore Delegato | 05/10/2011 |
Biotechnology Development for Industry in Pharmaceuticals SLU
Biotechnology Development for Industry in Pharmaceuticals SLU Miscellaneous Commercial ServicesCommercial Services Operates as an biotechnology company which produces recombinant proteins | Direttore/Membro del Consiglio | 13/09/2017 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 4 |
|---|---|
Dyadic International, Inc.
Dyadic International, Inc. Medical/Nursing ServicesHealth Services Manufactures genes and other biological products | Health Services |
University of Iowa
University of Iowa Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Dyadic International (USA), Inc.
Dyadic International (USA), Inc. BiotechnologyHealth Technology Researches and manufactures genes | Health Technology |
Biotechnology Development for Industry in Pharmaceuticals SLU
Biotechnology Development for Industry in Pharmaceuticals SLU Miscellaneous Commercial ServicesCommercial Services Operates as an biotechnology company which produces recombinant proteins | Commercial Services |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale